An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter

Endocrine ◽  
2008 ◽  
Vol 33 (2) ◽  
pp. 109-117 ◽  
Author(s):  
Geraldo Medeiros-Neto ◽  
Suemi Marui ◽  
Meyer Knobel
Keyword(s):  
Multinodular Goiter ◽  
Radioiodine Therapy ◽  
Recombinant Human Thyrotropin ◽  
Potential Use

scholarly journals Változások a pajzsmirigybetegségek radiojódkezelésében

2016 ◽  
Vol 157 (3) ◽  
pp. 83-88
Author(s):  
András Konrády
Keyword(s):  
Multinodular Goiter ◽  
Radioiodine Therapy ◽  
Treatment Protocol ◽  
Treatment Results ◽  
Radioiodine Uptake ◽  
Risk Patients ◽  
Toxic Multinodular Goiter ◽  
Prospective Trials ◽  
Immunogenic Hyperthyroidism ◽  
Recombinant Human Thyrotropin

Radioiodine therapy for benign and malignant thyroid diseases was introduced about 70 years ago, however, there is still a lack of consensus regarding indications, doses and procedure. This review covers treatment results in immunogenic hyperthyroidism including the problem of orbitopathy. Radioiodine therapy for toxic and non-toxic multinodular goiter is also discussed with striking possibility of enhanching the radioiodine uptake. In this respect the recombinant human thyrotropin should be mentioned. Thyroid cancer treatment protocol has changed, too, due to ineffectivity in low-risk patients. More attention is needed to the carcinogenecity of radioiodine. The numerous problems mentioned above require large and well-designed prospective trials to resolve the fundamental questions. The author emphasizes that radioiodine dose should be administered in doses as low as reasonably achievable. Orv. Hetil., 2016, 157(3), 83–88.

scholarly journals Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy in Patients with Multinodular Goiters: A Meta-Analysis of Randomized Controlled Trials

2020 ◽  
Vol 52 (12) ◽  
pp. 841-849
Author(s):  
Chunmei Xu ◽  
Ping Wang ◽  
Huikai Miao ◽  
Tianyue Xie ◽  
Xiaojun Zhou ◽  
...  
Keyword(s):  
Fixed Effects ◽  
Dose Group ◽  
Low Dose ◽  
Radioiodine Therapy ◽  
Meta Analysis ◽  
High Dose Group ◽  
High Dose ◽  
Fixed Effects Model ◽  
Recombinant Human Thyrotropin

AbstractA potential reduction of goiter volume (GV) of recombinant human thyrotropin (rhTSH) on multinodular goiters (MNG) was previously reported but controversial. Hence we conducted a meta-analysis to estimate the effect of rhTSH-stimulated radioiodine therapy in patients with MNG. PubMed, Cochrane, CNKI, VIP, and Wanfang databases were searched. Mean difference (MD) and odds ratios with 95% confidence intervals (95% CI) were derived by using an inverse variance random-effects model and fixed-effects model, respectively. Six studies (n=237) were involved in the analysis. For 12 months follow up, high dose (>0.1 mg) of rhTSH significantly reduced GV (MD=17.61; 95% CI=12.17 to 23.04; p<0.00001) compared with placebo. No effective pooled results of low dose of rhTSH (<0.1 mg) were applicable for only one study included. For 6 months follow up, the source of heterogeneity was determined by subgroup and sensitivity analysis. High dose group showed vast improvement in GV reduction (MD=16.62; 95% CI=1.34 to 31.90; p=0.03). The reduction of low dose group compared with placebo was inferior to high dose group. No available data were obtained to assess the influence of rhTSH after 36 months follow up for the only included study. Hypothyroidism incidence was higher for rhTSH group. No publication bias was seen. High dose of rhTSH treatment-stimulated radioactive 131I therapy after 6 months and 12 months follow up had a better effect in reducing GV, but with higher incidence of hypothyroidism. Owing to the limited methodological quality, more clinical researches are warranted in the future.

Radioiodine Therapy in Elderly Patients with Nontoxic Multinodular Goiter and High Cardiovascular Risk: A Safe Therapeutic Option?

2011 ◽  
pp. P2-700-P2-700
Author(s):  
Ricardo Andrade Oliveira ◽  
Priscila Alves Medeiros ◽  
Luciana Souza Caminha ◽  
Elisa Santos Pinto ◽  
Paula Bruna Araujo ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Elderly Patients ◽  
Multinodular Goiter ◽  
Radioiodine Therapy ◽  
Therapeutic Option ◽  
High Cardiovascular Risk

scholarly journals Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Patients with Metastatic Differentiated Thyroid Carcinoma

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Ivana Zagar ◽  
Andreja A. Schwarzbartl-Pevec ◽  
Barbara Vidergar-Kralj ◽  
Rika Horvat ◽  
Nikola Besic
Keyword(s):  
Thyroid Carcinoma ◽  
Total Thyroidectomy ◽  
Physical Condition ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma ◽  
Therapeutic Benefit ◽  
The Poor ◽  
Radioiodine Ablation ◽  
Recombinant Human Thyrotropin ◽  
Tsh Stimulation

Our aim was to test the efficacy of 131-I therapy (RIT) using recombinant human TSH (rhTSH) in patients with differentiated thyroid carcinoma (DTC) in whom endogenous TSH stimulation was not an option due to the poor patient's physical condition or due to the disease progression during L-thyroxin withdrawal. The study comprised 18 patients, who already have undergone total or near-total thyroidectomy and radioiodine ablation and 0–12 (median 5) RITs after L-thyroxin withdrawal. Our patients received altogether 44 RITs using rhTSH while on L-thyroxin. Six to 12 months after the first rhTSH-aided RIT, PR and SD was achieved in 3/18 (17%) and 4/18 patients (22%), respectively. In most patients (n= 12; 61%) disease progressed despite rhTSH-aided RITs. As a conclusion, rhTSH-aided RIT proved to add some therapeutic benefit in 39% our patients with metastatic DTC, who otherwise could not be efficiently treated with RIT.

scholarly journals Single, very low dose (0.03 mg) of recombinant human thyrotropin (rhTSH) effectively increases radioiodine uptake in the I-131 treatment of large nontoxic multinodular goiter

2016 ◽  
Vol 19 (1) ◽  
pp. 3-11 ◽  
Author(s):  
Małgorzata Natalia Mojsak ◽  
Saeid Abdelrazek ◽  
Piotr Szumowski ◽  
Franciszek Rogowski ◽  
Monika Sykała ◽  
...  
Keyword(s):  
Multinodular Goiter ◽  
Low Dose ◽  
Radioiodine Uptake ◽  
Recombinant Human Thyrotropin
Sign in / Sign up

Export Citation Format

Share Document